FIELD: immunology.
SUBSTANCE: what is presented is an anti-PD-L1 antibody or its antigen-binding fragment, a polynucleotide, an expression vector, a host cell. Also disclosed is a method of expressing an antibody or antigen-binding fragment thereof, a kit, a method for determining the presence or level of PD-L1, method of identifying an individual with a disorder or condition that can respond to a PD-L1 antagonist. What is also presented is a method for controlling a therapeutic response or disease progression, a pharmaceutical composition, a method of treating, using the antibody or its antigen-binding fragment.
EFFECT: present invention can find further application in therapy of malignant growth or chronic viral infection associated with PD-L1.
30 cl, 18 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| NEW ANTI-CD19 ANTIBODIES | 2018 |
|
RU2791445C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
